Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is poised for success with its strong clinical-stage pipeline and unique approach to targeting the Wnt pathway in retinal diseases. The company's lead product candidate, SZN-8141, has shown promising preclinical efficacy and has incorporated both Wnt pathway activation and VEGF inhibition, potentially providing greater efficacy and durability compared to currently available treatments. With increasing potential for investors as the company nears IND submission for SZN-8141 and continues to advance its other pipeline candidates, we maintain a positive outlook on Surrozen's stock.

Bears say

Surrozen is a clinical-stage biotechnology company, with a product candidate focused on selectively modulating the Wnt pathway for tissue repair in various organs. However, the company has not yet reached the phase of IND submission and there are risks associated with achieving peak commercial revenue. While their preclinical successes in retinopathy models are promising, there remains an unmet need for durable treatments and key data metrics such as durability and adoption rates are yet to be proven in clinical trials. Additionally, competition from other companies with Wnt pathway targeting development such as Merck could hinder Surrozen's success.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.